Literature DB >> 21663319

Convergent synthesis and biological evaluation of 2-amino-4-(3',4',5'-trimethoxyphenyl)-5-aryl thiazoles as microtubule targeting agents.

Romeo Romagnoli1, Pier Giovanni Baraldi, Andrea Brancale, Antonio Ricci, Ernest Hamel, Roberta Bortolozzi, Giuseppe Basso, Giampietro Viola.   

Abstract

Combretastatin A-4, a potent tubulin polymerization inhibitor, caused us to synthesize a novel series of 2-amino-4-(3',4',5'-trimethoxyphenyl)-5-aryl thiazoles with the goal of evaluating the effects of substituents on the phenyl at the 5-position of the thiazole skeleton on biological activities. An ethoxy group at the para-position produced the most active compound in the series, with IC(50) values of 0.03-0.9 nM against five of seven cancer cell lines. The most active compounds retained full activity in multidrug resistant cancer cells and acted through the colchicine site of tubulin. Treated cells were arrested in the G2/M phase of the cell cycle, with cell death proceeding through an apoptotic pathway that was only partially caspase-dependent. Preliminary results suggest that, in addition to cell death by apoptosis, cells were also killed via mitotic catastrophe as an alternative cell death mechanism.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21663319      PMCID: PMC3150540          DOI: 10.1021/jm200392p

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  56 in total

1.  Differential mitotic responses to microtubule-stabilizing and -destabilizing drugs.

Authors:  Jie-Guang Chen; Susan Band Horwitz
Journal:  Cancer Res       Date:  2002-04-01       Impact factor: 12.701

2.  Elevated levels of microtubule destabilizing factors in a Taxol-resistant/dependent A549 cell line with an alpha-tubulin mutation.

Authors:  Laura A Martello; Pascal Verdier-Pinard; Heng-Jia Shen; Lifeng He; Keila Torres; George A Orr; Susan Band Horwitz
Journal:  Cancer Res       Date:  2003-03-15       Impact factor: 12.701

3.  Novel B-ring modified combretastatin analogues: syntheses and antineoplastic activity.

Authors:  T Hatanaka; K Fujita; K Ohsumi; R Nakagawa; Y Fukuda; Y Nihei; Y Suga; Y Akiyama; T Tsuji
Journal:  Bioorg Med Chem Lett       Date:  1998-12-01       Impact factor: 2.823

Review 4.  Tubulin structure: insights into microtubule properties and functions.

Authors:  K H Downing; E Nogales
Journal:  Curr Opin Struct Biol       Date:  1998-12       Impact factor: 6.809

5.  Superoxide in apoptosis. Mitochondrial generation triggered by cytochrome c loss.

Authors:  J Cai; D P Jones
Journal:  J Biol Chem       Date:  1998-05-08       Impact factor: 5.157

6.  The development of combretastatin A4 phosphate as a vascular targeting agent.

Authors:  David J Chaplin; Sally A Hill
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-12-01       Impact factor: 7.038

7.  Potent, orally active heterocycle-based combretastatin A-4 analogues: synthesis, structure-activity relationship, pharmacokinetics, and in vivo antitumor activity evaluation.

Authors:  Le Wang; Keith W Woods; Qun Li; Kenneth J Barr; Richard W McCroskey; Steven M Hannick; Laura Gherke; R Bruce Credo; Yu-Hua Hui; Kennan Marsh; Robert Warner; Jang Y Lee; Nicolette Zielinski-Mozng; David Frost; Saul H Rosenberg; Hing L Sham
Journal:  J Med Chem       Date:  2002-04-11       Impact factor: 7.446

8.  Syntheses and antitumor activity of cis-restricted combretastatins: 5-membered heterocyclic analogues.

Authors:  K Ohsumi; T Hatanaka; K Fujita; R Nakagawa; Y Fukuda; Y Nihei; Y Suga; Y Morinaga; Y Akiyama; T Tsuji
Journal:  Bioorg Med Chem Lett       Date:  1998-11-17       Impact factor: 2.823

Review 9.  Combretastatin a-4 analogs as anticancer agents.

Authors:  Anurag Chaudhary; S N Pandeya; P Kumar; P P Sharma; S Gupta; N Soni; K K Verma; G Bhardwaj
Journal:  Mini Rev Med Chem       Date:  2007-12       Impact factor: 3.862

10.  Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl.

Authors:  S J Martin; C P Reutelingsperger; A J McGahon; J A Rader; R C van Schie; D M LaFace; D R Green
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

View more
  19 in total

1.  Design, synthesis and biological evaluation of arylcinnamide hybrid derivatives as novel anticancer agents.

Authors:  Romeo Romagnoli; Pier Giovanni Baraldi; Maria Kimatrai Salvador; Mariem Chayah; M Encarnacion Camacho; Filippo Prencipe; Ernest Hamel; Francesca Consolaro; Giuseppe Basso; Giampietro Viola
Journal:  Eur J Med Chem       Date:  2014-05-10       Impact factor: 6.514

2.  Molecular modeling study, synthesis and biological evaluation of combretastatin A-4 analogues as anticancer agents and tubulin inhibitors.

Authors:  Yang Ping Quan; Li Ping Cheng; Tian Chi Wang; Wan Pang; Fan Hong Wu; Jin Wen Huang
Journal:  Medchemcomm       Date:  2017-12-06       Impact factor: 3.597

Review 3.  An overview of tubulin inhibitors that interact with the colchicine binding site.

Authors:  Yan Lu; Jianjun Chen; Min Xiao; Wei Li; Duane D Miller
Journal:  Pharm Res       Date:  2012-07-20       Impact factor: 4.200

4.  Design, synthesis, in vitro, and in vivo anticancer and antiangiogenic activity of novel 3-arylaminobenzofuran derivatives targeting the colchicine site on tubulin.

Authors:  Romeo Romagnoli; Pier Giovanni Baraldi; Maria Kimatrai Salvador; Filippo Prencipe; Carlota Lopez-Cara; Santiago Schiaffino Ortega; Andrea Brancale; Ernest Hamel; Ignazio Castagliuolo; Stefania Mitola; Roberto Ronca; Roberta Bortolozzi; Elena Porcù; Giuseppe Basso; Giampietro Viola
Journal:  J Med Chem       Date:  2015-03-26       Impact factor: 7.446

5.  2-Alkoxycarbonyl-3-arylamino-5-substituted thiophenes as a novel class of antimicrotubule agents: Design, synthesis, cell growth and tubulin polymerization inhibition.

Authors:  Romeo Romagnoli; Maria Kimatrai Salvador; Santiago Schiaffino Ortega; Pier Giovanni Baraldi; Paola Oliva; Stefania Baraldi; Luisa Carlota Lopez-Cara; Andrea Brancale; Salvatore Ferla; Ernest Hamel; Jan Balzarini; Sandra Liekens; Elena Mattiuzzo; Giuseppe Basso; Giampietro Viola
Journal:  Eur J Med Chem       Date:  2018-01-01       Impact factor: 6.514

Review 6.  Celecoxib and Bcl-2: emerging possibilities for anticancer drug design.

Authors:  Leyte L Winfield; Florastina Payton-Stewart
Journal:  Future Med Chem       Date:  2012-03       Impact factor: 3.808

7.  Discovery of a Series of Thiazole Derivatives as Novel Inhibitors of Metastatic Cancer Cell Migration and Invasion.

Authors:  Shilong Zheng; Qiu Zhong; Quan Jiang; Madhusoodanan Mottamal; Qiang Zhang; Naijue Zhu; Matthew E Burow; Rebecca A Worthylake; Guangdi Wang
Journal:  ACS Med Chem Lett       Date:  2013-01-15       Impact factor: 4.345

8.  Cytotoxic 3,4,5-trimethoxychalcones as mitotic arresters and cell migration inhibitors.

Authors:  Lívia B Salum; Wanessa F Altei; Louise D Chiaradia; Marlon N S Cordeiro; Rafael R Canevarolo; Carolina P S Melo; Evelyn Winter; Bruno Mattei; Hikmat N Daghestani; Maria Cláudia Santos-Silva; Tânia B Creczynski-Pasa; Rosendo A Yunes; José A Yunes; Adriano D Andricopulo; Billy W Day; Ricardo J Nunes; Andreas Vogt
Journal:  Eur J Med Chem       Date:  2013-03-06       Impact factor: 6.514

9.  Novel 3-Substituted 7-Phenylpyrrolo[3,2-f]quinolin-9(6H)-ones as Single Entities with Multitarget Antiproliferative Activity.

Authors:  Davide Carta; Roberta Bortolozzi; Ernest Hamel; Giuseppe Basso; Stefano Moro; Giampietro Viola; Maria Grazia Ferlin
Journal:  J Med Chem       Date:  2015-10-07       Impact factor: 7.446

Review 10.  Thiazole Ring-A Biologically Active Scaffold.

Authors:  Anthi Petrou; Maria Fesatidou; Athina Geronikaki
Journal:  Molecules       Date:  2021-05-25       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.